| Literature DB >> 29189167 |
Priyanka Dhiman1, Neelam Malik1, Anurag Khatkar1.
Abstract
<span class="abstract_title">BACKGROUND: The computational development of <span class="Species">human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. The computational development of human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. Different natural heterocyclic structures are reported to display selective MAO inhibitory activity by preclinical and in-silico modeling.Entities:
Keywords: 3D-QSAR; CoMFA; in-silico docking; monoamine oxidase; natural monoamine oxidase inhibitors.
Mesh:
Substances:
Year: 2018 PMID: 29189167 PMCID: PMC6080100 DOI: 10.2174/1570159X15666171128143650
Source DB: PubMed Journal: Curr Neuropharmacol ISSN: 1570-159X Impact factor: 7.363
Fig. (1)Various interacting residues of naturally occurring flavanoids.
Natural MAO inhibitors along with targeted disorders utilized molecular docking.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1. | MAO-A | Eugenol and derivatives | Antidepressant | AutoDock 3.0 | Tao |
| 2. | MAO-B | 8-(3-Chlorostrylyl)caffeine | Neuroprotective | AutoDock 3.0.5 | Toprakci |
| 3. | MAO-A and MAO-B | Fucoxanthin | Parkinson’s disease | Autodock 4.0 | Jung |
| 4. | MAO-A and MAO-B | Eckol and dieckol | Parkinson’s disease | Autodock | Jung |
| 5. | MAO-A | Decursin | Neuroprotective | Autodock 4.2 | Lee |
| 6. | MAO-B | Homoisoflavonoid Mannich base derivatives | Alzheimer’s disease | Discovery Studio 2.5 | Li |
| 7. | MAO-A and MAO-B | Thioxanthone | Alzheimer’s disease | Discovery Studio 2.5 | Luo et al., 2017 [ |
| 8. | MAO-A and MAO-B | Flavone Derivatives | Neurodegenerative disorders | Schrodinger | Jia et al., 2017 [ |
Molecular docking profile of natural ligands for MAO isoforms.
|
|
|
|
|---|---|---|
| Docking Score (trough standard precision method | -8.400 and -5.726 | -9.411 to -6.739 |
| Docking Score (through standard precision method | -12.128 and -5.683 | -11.122 to -6.987. |
| π- π staking | Tyr444, Phe208, Tyr407, and Phe352 | Tyr398, Tyr435and Tyr326 |
| H-Bond | Asn181, Tyr197, and Tyr444 | Cys 172, Tyr188, and Tyr435 |
MAO inhibition by natural components of psoralea corylifolia evaluated by docking.
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
| 1. | Bavachin | -8.69 | H2O-726 | -3.95 | 0 | ... | ... | NA |
| 2. | Bavachinin | -1.54 | 0 | -6.82 | 2 | HO ... HN | THR: 201: A | B |
| 3. | Safinamide | -0.25 | 0 | -6.12 | 3 | NH ... O | THR: 201: A | B |
Molecular docking studies of DZ and GST within 3D crystallographic structure of monoamine oxidase-A and –B isoforms.
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| 1. | Daidzein (DZ) | −6.8 | 0 | −12.8 | 1 (O … HN) | 2.32 | THR: 201: A |
| 2. | Genistein (GST) | −7.3 | 0 | −12.8 | 2 (OH … N) | 2.27 | THR: 201: A |
Molecular docking of natural compounds isolated from Clitoria ternatea for MAO isoforms.
|
|
|
|
|
|
|---|---|---|---|---|
| 1. | Kaempferol-monoglucoside | -14.9178 (MAO-A) | 7(MAO-A) | ASN181, GLN443,GLN66,GLN443, MET445, TYR69, ALA 68 (MAO-A) LYS 296, TYR 60, GLY 434 (MAO-B) |
| 2. | Malvidin-3-0-glucoside | -7.86773 (MAO-A) | 3 (MAO-A) | TYR 69, GLN215, ALA 68 |
| 3. | n-Hexadecanoic acid | -5.4457 (MAO-A) | 3 (MAO-A) | ALA 68, MET 445, ALA 68 (MAO-A) |
| 4. | Quercetin | -11.4556 (MAO-A) | 2 (MAO-A) | ASN 181, PHE 208 (MAO-A) |
(Z)- 9,17-octadecadienal and monoamine oxidase A contributed by the amino acid residues ALA68 and TYR69 though important collaboration between n-hexadecanoic acid and monoamine oxidase A were contributed by the amino acid residues MET 445 and ALA68. Moreover, docked kaempferol-3-monoglucoside showed a minimum score of - 13.90/ - 12.95 kcal/mol. The two compounds, (Z)-9,17-octadecadienal showed low restricting binding affinity energy estimation of -6.5/-7.71 kcal/mol against both the MAO isoforms whereas, n-hexadecanoic acid with a minimum docking score of - 10.5001 kcal/mol against MAO-B facilitated as potential lead molecules for further design of novel MAO inhibitors (Table ).
Major binding interactions of Alkaloids resulted by docking studies.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1. | Morpholine derivatives | Tyr326 | _ | Autodock 4.0 | Lühr |
| 2. | Piperine | Tyr 188, Gln 206 Cys 172, Tyr 326, Thr 201 and Ileu 199 | _ | Schrödinger | Mu |
| 3. | Menadione (vitamin K3) | Tyr398 and Tyr435 (for MAO-A) | _ | AutoDock 4.0 | Cerqueira |
| 4. | Amphetamine | Tyr197 | Tyr407 | AutoDockVina | Fresqui |
| 5. | Quinazoline | GLN 74, ILE 207, and TYR 444 SER 209 and GLU 216 | _ | MOE-Dock | Khattab |
| 6. | Nicotinamide | Tyr 444, Asn181 and Tyr 197 | Tyr407 | AUTODOCKTOOLS (ADT) | Shi |
| 7. | Caffeine | Tyr444, Tyr435 | _ | Autodock 4.0 | Petzer |
| 8. | Psychotria alkaloids | WAT-746 | Tyr-407 | GOLD | Son |
Docking profile of psychotria alkaloids and their major interactions.
Docking studied of curcumin with MAO enzyme.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1. | Curcumin | -3.20 | 12.98 | 12 | 274 PRO,51 ARG, 52THR, 43 GLU, 407 TYR, 23 ILE, 277 LEU, 45ARG, 402 TYR, 445 MET, 273 ILE, 448 ALA |
| 2. | Brofaromine (Standard) | -7.53 | 3.08 | 10 | 445 MET, 52 THR, 406 CYS,448 ALA, 303 VAL, 51 ARG,397, 305 LYS, TRP, 407 TYR, 435 THR |
Molecular docking profile of curcumin studied for MAO isoforms inhibition.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1. | Curcumin (MAO-B) | -7.80 | 1.89 µM | - | TYR398, MET436, TYR326, PHE343 | PHE343, TYR398 |
| 2. | Curcumin (MAO-A) | -7.96 | 1.56 µM | - | TYR69, ILE23, ILE180, ILE335, PHE352, TYR407 | TYR407, PHE352 |